Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
First gene replacement therapy in the EU for broad population with SMA, including children two years and older,…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…